At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
Bortezomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation
Children's Hospital Medical Center, Cincinnati·interventional·Posted Aug 28, 2013·Updated Oct 24, 2016
In Brief
A Phase 2 clinical trial evaluating Bortezomib for Allogeneic Stem Cell Transplantation and Refractory Autoimmune Cytopenia(s). Completed, enrolled 4 participants across 1 site.
Detailed Summary
The purpose of this trial is to study the safety and effectiveness of a drug called Bortezomib for the treatment of low blood cell counts after bone marrow transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedAug 2013
Primary CompletionMay 2014
TodayJul 2026
First PostedAug 28, 2013
Enrollment StartJul 1, 2012
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.8 years ago
Interventions
Bortezomibdrug